Press Releases

 
Press Releases
  Date Title and Summary View
May 18, 2017
AMES, Iowa, May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous leukemia (AML), is now available on the website of t...
May 17, 2017
AMES, Iowa, May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017 American Society of Clinical Oncology (ASCO) Annual ...
May 8, 2017
AMES, Iowa, May 08, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference on May 18 in Las Vegas, NVJefferies 2017 Global Healthcare Conference on June 8 at 11:30am ET in New York City...
May 4, 2017
AMES, Iowa, May 04, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported consolidated financial results for the first quarter 2017, as well as progress in its clinical development programs. Recent Highlights: Presented promising interim Phase 2 data of the IDO pathway inhibitor, indoximod, in combination with ...
Apr 21, 2017
AMES, Iowa, April 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Abstract 10...
Apr 13, 2017
AMES, Iowa, April 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development acti...
Apr 4, 2017
AMES, Iowa, April 04, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported interim results from NLG2103, a Phase 2 study evaluating its IDO pathway inhibitor, indoximod, in combination with checkpoint inhibitors ...
Mar 1, 2017
AMES, Iowa, March 01, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts on the company's indoximod program will be presented at the American Association for Cancer Research (AACR) 2017 Annua...
Feb 28, 2017
AMES, Iowa, Feb. 28, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported consolidated financial results for the fourth quarter and year ended 2016, as well as progress in its clinical development programs. NewLi...
Feb 20, 2017
AMES, Iowa, Feb. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its fourth quarter and year end 2016 financial results on Tuesday, February 28, 2017.  The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and bu...
Page:
1
... NextLast
= add release to Briefcase